CRESO2: Effects of Caloric Restriction in Obesity and Type 2 Diabetes

Sponsor
Mario Negri Institute for Pharmacological Research (Other)
Overall Status
Completed
CT.gov ID
NCT01930136
Collaborator
Istituto Superiore di Sanità (Other)
103
1
2
108.1
1

Study Details

Study Description

Brief Summary

The study investigates whether a long-term 25% caloric restriction can prevent onset and/or progression of renal function deterioration, retinal involvement and cardiovascular complications in overweight/obese type 2 diabetic patients, trough the amelioration of concomitant metabolic abnormalities such as visceral obesity, insulin resistance, dyslipidemia, hypertension and inflammation.

The main aim of the study is therefore to evaluate the role of calorie restriction (CR) on subjects at risk of nephropathy. Secondary aims are to better understand the relationship between CR and the following aspects: renal disease and its associated metabolic abnormalities, retinopathy and cardiovascular complications, quality of life and treatment cost.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Calorie restriction (25%)
  • Behavioral: Ad libitum health diet
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
103 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Long-term Effects of Caloric Restriction on Metabolic, Renal End Retinal Health in Subjectsaffected by Obesityand Type 2 Diabetes
Actual Study Start Date :
May 1, 2013
Actual Primary Completion Date :
May 5, 2022
Actual Study Completion Date :
May 5, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Calorie restriction (25%)

CR will correspond to a reduction of 25% from the total daily calorie expenditure calculated as Total Daily Energy Expenditure (TDEE) (kcal/d) using the formula from the validated Seven-Day Physical Activity Recall (PAR) Questionnaire (RMR x activity levels).

Behavioral: Calorie restriction (25%)

Active Comparator: Ad libitum health diet

Behavioral: Ad libitum health diet

Outcome Measures

Primary Outcome Measures

  1. The percent change in glomerular filtration rate (GFR) at month 6 versus baseline and the rate of GFR decline from month 6 to study end [At baseline, 6, 12 and 24 month]

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria

  • Age >40 years;

  • Type 2 diabetes (ADA criteria);

  • UAE <300 mg/24h;

  • Body mass index (BMI)>27kg/m2;

  • Serum creatinine < 1.2 mg/dL;

  • No major changes in calorie, protein and sodium intake in the last 6 mos;

  • No major changes in concomitant treatments with blood pressure, glucose or lipid lowering agents since 6 and 3 months respectively;

  • Patients legally able to give written informed consent to the trial (signed and dated by the patient);

  • Written informed consent.

Exclusion Criteria

  • Concomitant non-diabetic renal disease or ischemic kidney disease;

  • Primary or immune-mediated renal disease;

  • Urinary tract obstruction or infection;

  • Treatment with steroids and/or non-steroid anti-inflammatory agents;

  • Treatment with thiazide or loop diuretics that, on the basis of the Investigator's judgment, might sustain hypovolemia and/or sodium depletion (with secondary kidney hypoperfusion/hypofiltration);

  • Hearth failure and/or hemodynamically significant left ventricular systolic dysfunction, cirrhosis, uncontrolled hyperglycemia resulting in glycosuria, hyper/hyponatremia of any cause;

  • Previous surgical procedures for weight loss;

  • Previous episodes of depression, or suicide attempts;

  • Chronic abuse of alcohol and drugs;

  • Pregnancy, ineffective contraception or peri-menopausal age;

  • Cancer or any chronic disease that might affect the completion of the study;

  • Chronic obstructive pulmonary disease (COPD) in treatment with positive airway pressure;

  • Unwillingness or inability to adhere to CR intervention over the entire 24-months intervention period;

  • Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial;

  • Evidence of an uncooperative attitude;

  • Any evidence that patient will not be able to complete the trial follow-up;

  • Inability to fully understand the potential risks and benefits of the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinical Research Center for Rare Diseases Ranica Bergamo Italy 24020

Sponsors and Collaborators

  • Mario Negri Institute for Pharmacological Research
  • Istituto Superiore di Sanità

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mario Negri Institute for Pharmacological Research
ClinicalTrials.gov Identifier:
NCT01930136
Other Study ID Numbers:
  • CRESO 2
First Posted:
Aug 28, 2013
Last Update Posted:
May 6, 2022
Last Verified:
May 1, 2022
Keywords provided by Mario Negri Institute for Pharmacological Research
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2022